The humble bumblebee, a creature often perceived as a small, buzzing garden visitor, plays an outsized and indispensable role in…
Read More
Andean leaf-eared mice living at high altitude make more heat than those at sea level
The remarkable adaptability of life at Earth’s extremes is underscored by a recent study revealing how the Andean leaf-eared mouse…
Read More
Groundbreaking Network Maps Pathobiological Impact of Chemical Exposures on Molecular Level, Informing Public Health Strategies
A pioneering study led by researchers at the Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM)…
Read More
The ‘Entry-Level’ Gatekeeper: Auditing Job Descriptions with Textstat for Enhanced Accessibility and Inclusivity.
The modern recruitment landscape frequently presents a perplexing paradox: "entry-level" job descriptions laden with dense, impenetrable jargon that inadvertently deter…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
The pharmaceutical industry’s financial landscape underwent a significant reordering in fiscal year 2025, as revealed by the latest "Pharma 50"…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025.
The pharmaceutical industry witnessed a significant shift in its commercial landscape during Fiscal Year 2025, with Merck’s oncology powerhouse, Keytruda…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
Merck’s immunotherapy blockbuster, Keytruda (pembrolizumab), maintained its dominant position as the pharmaceutical industry’s leading brand in Fiscal Year 2025, recording…
Read More
Pharma 50: Keytruda Holds Top Brand Slot, But Tirzepatide and Semaglutide Have Already Passed It at the Molecule Level in FY2025
Merck’s Keytruda (pembrolizumab) maintained its formidable position as the pharmaceutical industry’s leading brand in Fiscal Year 2025, recording an impressive…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
The pharmaceutical industry’s financial landscape is undergoing a significant transformation, marked by the continued brand dominance of Merck’s Keytruda (pembrolizumab)…
Read More
Pharma 50: Keytruda Holds Top Brand Slot as Tirzepatide and Semaglutide Dominate at Molecule Level in FY2025
The pharmaceutical industry’s financial landscape underwent a significant transformation in fiscal year 2025, revealing a nuanced shift in leadership despite…
Read More
